Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **China Pharma and Biotech** industry, identifying potential winners in the sector as part of the "China Next Winners" series [1] Core Insights and Arguments - **Out-licensing Trends**: While out-licensing is a key trend, it does not guarantee value creation. Success depends on global trial results and market access strategies. Stock picking based on fundamentals is expected to become more critical as market volatility increases [2][6] - **Identified Winners**: Among 30 companies analyzed, **Hengrui** and **Innovent** are consistently high performers. Other notable mentions include **BeOne** (formerly BeiGene) and **CSPC**, with potential rising stars like **Kelun Biotech**, **Duality**, **3S Bio**, and **Biokin** [2][10] - **Total Addressable Market (TAM)**: Hengrui, CSPC, and Innovent cover a wide range of diseases, tapping into a TAM of approximately **$200 billion** in oncology, **$120 billion+** in cardiovascular and metabolism, **$70 billion+** in autoimmune, and **$40 billion+** in respiratory diseases [3][29] - **Pipeline Competitiveness**: The quality of a company's pipeline is assessed based on the number of assets, innovation levels, and competitive trial results. Hengrui, BeOne, and Akeso score highest in pipeline competitiveness [3][31] - **Globalization Metrics**: Companies are evaluated on their globalization progress through out-licensing deals and direct market access metrics. Hengrui and BeOne are leading in this area, with significant cash reserves to support R&D [4][23] - **RNAi Sector Potential**: The RNA interference (RNAi) sector is emerging, with FDA-approved therapies generating peak sales over **$15 billion**. Hengrui and CSPC are positioned well in this niche market [5] Investment Recommendations - Current market conditions suggest that investors should avoid chasing stocks. Instead, a strategy focused on careful stock selection during sector-wide corrections is recommended [6][8] Financial Metrics and Valuations - The report includes a detailed **Bernstein Ticker Table** summarizing the performance and valuations of various companies, indicating that **Hengrui** and **Innovent** are rated as outperformers, while **BeiGene**, **Zai Lab**, **Sino Biopharm**, and **CSPC** are rated as market performers [7][8] Additional Insights - The healthcare sector in China has shown significant growth, with expectations of continued volatility. The focus on stock picking is emphasized as a strategy for navigating the market [9][10] - The report highlights the importance of both pipeline size and quality in assessing a company's competitiveness, with metrics including the number of assets and the percentage of first-in-class innovations [31] Conclusion - The China Pharma and Biotech industry presents numerous investment opportunities, particularly among companies with strong fundamentals, innovative pipelines, and effective globalization strategies. The focus on specific therapeutic areas and the potential of emerging sectors like RNAi further enhance the attractiveness of this market [29][30][33]

Core Viewpoint - Junshi Biosciences announced the acceptance of a supplemental new drug application for toripalimab in combination with disitamab vedotin for treating HER2-expressing locally advanced or metastatic urothelial carcinoma, marking toripalimab's 13th marketing application in mainland China [1] Group 1: Company Overview - Junshi Biosciences is an innovation-driven biopharmaceutical company focused on discovering, developing, and commercializing novel therapies, with a diversified R&D pipeline of over 50 drug candidates [11] - The company has five therapeutic focus areas: cancer, autoimmune, metabolic, neurological, and infectious diseases, and has received approvals for five products in China and international markets [11] - Toripalimab is China's first domestically produced and independently developed anti-PD-1 monoclonal antibody, approved in 40 countries and regions, including China, the US, and Europe [11][10] Group 2: Industry Context - Urothelial carcinoma (UC) is one of the ten most prevalent malignant tumors globally, with rising incidence and mortality rates in China; in 2022, there were 92,900 new cases and over 40,000 deaths [2] - The treatment landscape for advanced UC has been reshaped by the emergence of PD-(L)1 monoclonal antibodies and novel antibody-drug conjugates (ADCs), offering significant improvements in survival benefits and tolerability compared to conventional chemotherapy [3] - The RC48-C016 study demonstrated that toripalimab combined with disitamab vedotin significantly improved progression-free survival (PFS) and overall survival (OS) compared to traditional chemotherapy regimens [5][4]